BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9537232)

  • 1. A large deletion disrupts the exon 3 transcription activation domain of the BRCA2 gene in a breast/ovarian cancer family.
    Nordling M; Karlsson P; Wahlström J; Engwall Y; Wallgren A; Martinsson T
    Cancer Res; 1998 Apr; 58(7):1372-5. PubMed ID: 9537232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutation analysis of the BRCA1 and BRCA2 genes results in the identification of novel and recurrent mutations in 6/16 flemish families with breast and/or ovarian cancer but not in 12 sporadic patients with early-onset disease. Mutations in brief no. 224. Online.
    Claes K; Machackova E; De Vos M; Mortier G; De Paepe A; Messiaen L
    Hum Mutat; 1999; 13(3):256. PubMed ID: 10090482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators.
    Gayther SA; de Foy KA; Harrington P; Pharoah P; Dunsmuir WD; Edwards SM; Gillett C; Ardern-Jones A; Dearnaley DP; Easton DF; Ford D; Shearer RJ; Kirby RS; Dowe AL; Kelly J; Stratton MR; Ponder BA; Barnes D; Eeles RA
    Cancer Res; 2000 Aug; 60(16):4513-8. PubMed ID: 10969800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families.
    Durocher F; Labrie Y; Soucy P; Sinilnikova O; Labuda D; Bessette P; Chiquette J; Laframboise R; Lépine J; Lespérance B; Ouellette G; Pichette R; Plante M; Tavtigian SV; Simard J
    BMC Cancer; 2006 Sep; 6():230. PubMed ID: 17010193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for BRCA2 mutations in 81 Dutch breast-ovarian cancer families.
    Peelen T; van Vliet M; Bosch A; Bignell G; Vasen HF; Klijn JG; Meijers-Heijboer H; Stratton M; van Ommen GJ; Cornelisse CJ; Devilee P
    Br J Cancer; 2000 Jan; 82(1):151-6. PubMed ID: 10638982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel germline in frame deletion (4128del3) of the BRCA2 gene detected in a breast/ovarian cancer family with fallopian tube and brain tumors identified in the north of France.
    Demange L; Noguchi T; Sauvan R; Moyal-Amsellem N; Birnbaum D; Eisinger F; Sobol H
    Hum Mutat; 2001 Feb; 17(2):155. PubMed ID: 11180606
    [No Abstract]   [Full Text] [Related]  

  • 7. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes.
    Thorlacius S; Olafsdottir G; Tryggvadottir L; Neuhausen S; Jonasson JG; Tavtigian SV; Tulinius H; Ogmundsdottir HM; Eyfjörd JE
    Nat Genet; 1996 May; 13(1):117-9. PubMed ID: 8673089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA2 mutations in primary breast and ovarian cancers.
    Lancaster JM; Wooster R; Mangion J; Phelan CM; Cochran C; Gumbs C; Seal S; Barfoot R; Collins N; Bignell G; Patel S; Hamoudi R; Larsson C; Wiseman RW; Berchuck A; Iglehart JD; Marks JR; Ashworth A; Stratton MR; Futreal PA
    Nat Genet; 1996 Jun; 13(2):238-40. PubMed ID: 8640235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Large BRCA1 and BRCA2 genomic rearrangements in Danish high risk breast-ovarian cancer families.
    Hansen Tv; Jønson L; Albrechtsen A; Andersen MK; Ejlertsen B; Nielsen FC
    Breast Cancer Res Treat; 2009 May; 115(2):315-23. PubMed ID: 18546071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A deletion/insertion mutation in the BRCA2 gene in a breast cancer family: a possible role of the Alu-polyA tail in the evolution of the deletion.
    Wang T; Lerer I; Gueta Z; Sagi M; Kadouri L; Peretz T; Abeliovich D
    Genes Chromosomes Cancer; 2001 May; 31(1):91-5. PubMed ID: 11284040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening of male breast cancer and of breast-ovarian cancer families for BRCA2 mutations using large bifluorescent amplicons.
    Pages S; Caux V; Stoppa-Lyonnet D; Tosi M
    Br J Cancer; 2001 Feb; 84(4):482-8. PubMed ID: 11207042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of ten novel and 13 recurring BRCA1 and BRCA2 germline mutations in Italian breast and/or ovarian carcinoma patients. Mutations in brief no. 178. Online.
    De Benedetti VM; Radice P; Pasini B; Stagi L; Pensotti V; Mondini P; Manoukian S; Conti A; Spatti G; Rilke F; Pierotti MA
    Hum Mutat; 1998; 12(3):215. PubMed ID: 10660329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a novel BRCA1 large genomic rearrangement in a Spanish breast/ovarian cancer family.
    Palanca Suela S; Esteban Cardeñosa E; Barragán González E; Oltra Soler S; de Juan Jiménez I; Chirivella González I; Segura Huerta A; Guillén Ponce C; Martínez de Dueñas E; Bolufer Gilabert P;
    Breast Cancer Res Treat; 2008 Nov; 112(1):63-7. PubMed ID: 18060491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gross rearrangements in BRCA1 but not BRCA2 play a notable role in predisposition to breast and ovarian cancer in high-risk families of German origin.
    Preisler-Adams S; Schönbuchner I; Fiebig B; Welling B; Dworniczak B; Weber BH
    Cancer Genet Cytogenet; 2006 Jul; 168(1):44-9. PubMed ID: 16772120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency of BRCA1 and BRCA2 mutations in a clinic-based series of breast and ovarian cancer families.
    Vaziri SA; Krumroy LM; Rostai M; Casey G
    Hum Mutat; 2001; 17(1):74. PubMed ID: 11139249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients.
    Johannesdottir G; Gudmundsson J; Bergthorsson JT; Arason A; Agnarsson BA; Eiriksdottir G; Johannsson OT; Borg A; Ingvarsson S; Easton DF; Egilsson V; Barkardottir RB
    Cancer Res; 1996 Aug; 56(16):3663-5. PubMed ID: 8706004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome?
    Goshen R; Chu W; Elit L; Pal T; Hakimi J; Ackerman I; Fyles A; Mitchell M; Narod SA
    Gynecol Oncol; 2000 Dec; 79(3):477-81. PubMed ID: 11104623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
    Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High frequency of recurrent mutations in BRCA1 and BRCA2 genes in Polish families with breast and ovarian cancer.
    Grzybowska E; Zientek H; Jasinska A; Rusin M; Kozlowski P; Sobczak K; Sikorska A; Kwiatkowska E; Gorniak L; Kalinowska E; Utracka-Hutka B; Wloch J; Chmielik E; Krzyzosiak WJ
    Hum Mutat; 2000 Dec; 16(6):482-90. PubMed ID: 11102977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.